These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 36747765)

  • 1. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Nugent C; Abul Y; White E; Shehadeh F; Kaczynski M; Felix LO; Ganesan N; Oyebanji OA; Vishnepolskiy I; Didion EM; Paxitzis A; Sheehan ML; Mylonakis E; Wilson BM; Balazs AB; Chan PA; King CL; Pfeifer WM; Dickerson E; Canaday DH; Gravenstein S
    medRxiv; 2023 Jan; ():. PubMed ID: 36747765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Nugent C; Abul Y; White EM; Shehadeh F; Kaczynski M; Oscar Felix L; Ganesan N; Oyebanji OA; Vishnepolskiy I; Didion EM; Paxitzis A; Sheehan ML; Chan PA; Pfeifer WM; Dickerson E; Kamojjala S; Wilson BM; Mylonakis E; King CL; Balazs AB; Canaday DH; Gravenstein S
    Vaccine; 2023 May; 41(22):3403-3409. PubMed ID: 37117056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
    Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB
    medRxiv; 2024 Mar; ():. PubMed ID: 38585784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
    Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
    Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
    McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers.
    Freeman ML; Oyebanji OA; Moisi D; Payne M; Sheehan ML; Balazs AB; Bosch J; King CL; Gravenstein S; Lederman MM; Canaday DH
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad063. PubMed ID: 36861088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significantly elevated antibody levels and neutralization titers in nursing home residents after SARS-CoV-2 BNT162b2 mRNA booster vaccination.
    Canaday DH; Oyebanji OA; White E; Keresztesy D; Payne M; Wilk D; Carias L; Aung H; St Denis K; Sheehan ML; Berry SD; Cameron CM; Cameron MJ; Wilson BM; Balazs AB; King CL; Gravenstein S
    medRxiv; 2021 Dec; ():. PubMed ID: 34909792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers.
    Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J
    J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
    Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
    J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
    Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
    Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers.
    Oyebanji OA; Sundheimer N; Ragavapuram V; Wilson BM; Abul Y; Gravenstein S; Bosch J; King CL; Canaday DH
    Geroscience; 2024 Dec; 46(6):6183-6194. PubMed ID: 38789833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.
    Khan S; Hosseinian S; Assis R; Khalil G; Luu M; Jain A; Horvath P; Nakajima R; Palma A; Hoang A; Razzak E; Garcia N; Alger J; Kalantari M; Silzel E; Jasinskas A; Zaldivar F; Schubl S; Felgner P
    Res Sq; 2022 Dec; ():. PubMed ID: 36561177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan.
    Kakugawa T; Doi K; Ohteru Y; Kakugawa H; Oishi K; Kakugawa M; Hirano T; Mimura Y; Matsunaga K
    Immun Ageing; 2023 Aug; 20(1):42. PubMed ID: 37592283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.